Ultra Market Research | United Kingdom Irinotecan Market
United Kingdom Irinotecan Market
Report ID : 964
Category : Therapeutic-Area,United-Kingdom(UK)
No Of Pages : 99
Published on: January 2025
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
United Kingdom Irinotecan Market Introduction United Kingdom Irinotecan Market United Kingdom Irinotecan Market United Kingdom is an emerging sector of the pharmaceutical market. This segment has experienced fast-paced growth because it is highly associated with the field of oncology, mainly used in colorectal cancer. The topoisomerase inhibitor Irinotecan plays a vital role in combination chemotherapy regimen FOLFIRI. Recent years have shown considerable growth because of increasing prevalence of cancer and the emergence of advanced treatment plans. The UK market size for irinotecan was estimated to be around USD 150 million in 2024, with a projected CAGR of 6.5% from 2024 to 2030. Recent trends indicate a shift towards personalized medicine and the introduction of liposomal formulations for improved efficacy and reduced side effects, which is contributing to the steady growth trajectory of the market.
Segmentation Drug Types • Generic Irinotecan o Irinotecan Hydrochloride o Liposomal Irinotecan o Others • Branded Irinotecan o Onivyde (Liposomal Irinotecan) o Camptosar • Others o Experimental Formulations
Indications • Colorectal Cancer o Stage III Colorectal Cancer o Stage IV Colorectal Cancer o Others • Lung Cancer o Non-Small Cell Lung Cancer (NSCLC) o Small Cell Lung Cancer (SCLC) • Pancreatic Cancer o Advanced Pancreatic Cancer o Metastatic Pancreatic Cancer • Others
Distribution Channels • Hospital Pharmacies o Public Hospitals o Private Hospitals • Retail Pharmacies o Independent Pharmacies o Chain Pharmacies • Online Pharmacies
Drivers United Kingdom market for irinotecan is increasing because of the high incidence of cancer. Colorectal cancer continues to be one of the most commonly diagnosed cancers in the UK. The treatment strategy of patients often involves irinotecan-based drugs. Recent formulation advancements, like liposomal irinotecan, have shown a great deal of promise, with a higher patient benefit, due to its lower side effect profile and enhanced bioavailability. Besides, improvements in healthcare infrastructures and related government initiatives aimed at cancer research are further supporting the growth in the market. The increasing knowledge about chemotherapy therapies and the release of biosimilars help make irinotecan more affordable and available.
Restraints Market is however, challenged by the lengthy drug approval process in this prospect, which is prolonged due to strict regulatory frameworks. High treatment costs and other side effects, including severe diarrhea and neutropenia associated with irinotecan, can lower patient compliance. The market growth is threatened with alternative therapies like targeted drugs and immunotherapy. It further hampers mass adoption due to lack of awareness and accessibility in rural areas and budget constraints in public healthcare systems.
Opportunities United Kingdom Irinotecan Market has vast opportunities due to continuous R&D. Next-generation formulations, such as nanoparticle-based irinotecan, have the potential to provide better therapeutic outcomes. Precision medicine and biomarker-based patient stratification are increasingly being adopted, creating a niche for irinotecan in personalized oncology. Expanding healthcare coverage and public-private partnerships to improve drug accessibility also provide lucrative growth avenues. Furthermore, the growing emphasis on value-based healthcare models is encouraging the adoption of cost-effective chemotherapy options, benefiting irinotecan manufacturers.
Trend Latest trend in the United Kingdom Irinotecan Market is the integration of artificial intelligence in drug development and patient management. AI-powered algorithms are enabling faster identification of potential candidates for irinotecan therapy based on genetic profiling. The rise of digital health platforms is streamlining patient monitoring during chemotherapy, reducing hospital visits. Additionally, the market is seeing more and more collaboration between pharmaceutical companies and research institutes to develop innovative delivery systems such as liposomes and nanoparticles for irinotecan, thus increasing its efficacy. The rise of biosimilars is also changing the competitive dynamics and making the treatment more affordable and accessible.
Approved Products and Pipeline • Approved Products: o Onivyde (Liposomal Irinotecan) o Camptosar o Irinotecan Hydrochloride • Pipeline Products: o Liposomal Irinotecan for Pancreatic Cancer (Phase III) o Nanoparticle Formulation of Irinotecan (Pre-clinical) o Combination Therapy of Irinotecan and Immunotherapy Agents (Phase II)
Key Target Audience • Oncologists and Healthcare Providers • Pharmaceutical Manufacturers • Contract Research Organizations (CROs) • Academic and Research Institutions • Regulatory Authorities • Healthcare Policy Makers • Distributors and Wholesalers
Frequently Asked Questions (FAQ's)
Rising cancer prevalence, advancements in drug formulations, and growing healthcare investments are key drivers.
Pfizer, Sandoz, Teva, and Accord Healthcare are notable players.
High costs, side effects, and competition from alternative therapies are significant challenges.
R&D in precision medicine, innovative formulations, and expanding healthcare coverage are major opportunities.
Integration of AI in patient management, development of biosimilars, and innovative delivery systems are key trends.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis
2. Market Dashboard
3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Drug Types • Generic Irinotecan o Irinotecan Hydrochloride o Liposomal Irinotecan o Others • Branded Irinotecan o Onivyde (Liposomal Irinotecan) o Camptosar • Others 3.2.2 By Indications • Colorectal Cancer o Stage III Colorectal Cancer o Stage IV Colorectal Cancer o Others • Lung Cancer o Non-Small Cell Lung Cancer (NSCLC) o Small Cell Lung Cancer (SCLC) • Pancreatic Cancer o Advanced Pancreatic Cancer o Metastatic Pancreatic Cancer • Others 3.2.3 By Distribution Channels • Hospital Pharmacies o Public Hospitals o Private Hospitals • Retail Pharmacies o Independent Pharmacies o Chain Pharmacies • Online Pharmacies 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges
4. United Kingdom Irinotecan Market by Drug Types 4.1 Introduction 4.2 Market Size and Growth Rate by Drug Types (2024–2030) 4.2.1 Generic Irinotecan 4.2.1.1 Irinotecan Hydrochloride 4.2.1.2 Liposomal Irinotecan 4.2.1.3 Others 4.2.2 Branded Irinotecan 4.2.2.1 Onivyde (Liposomal Irinotecan) 4.2.2.2 Camptosar 4.2.3 Others
5. United Kingdom Irinotecan Market by Indications 5.1 Introduction 5.2 Market Size and Growth Rate by Indications (2024–2030) 5.2.1 Colorectal Cancer 5.2.1.1 Stage III Colorectal Cancer 5.2.1.2 Stage IV Colorectal Cancer 5.2.1.3 Others 5.2.2 Lung Cancer 5.2.2.1 Non-Small Cell Lung Cancer (NSCLC) 5.2.2.2 Small Cell Lung Cancer (SCLC) 5.2.3 Pancreatic Cancer 5.2.3.1 Advanced Pancreatic Cancer 5.2.3.2 Metastatic Pancreatic Cancer 5.2.4 Others
6. United Kingdom Irinotecan Market by Distribution Channels 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channels (2024–2030) 6.2.1 Hospital Pharmacies 6.2.1.1 Public Hospitals 6.2.1.2 Private Hospitals 6.2.2 Retail Pharmacies 6.2.2.1 Independent Pharmacies 6.2.2.2 Chain Pharmacies 6.2.3 Online Pharmacies
9. Appendix 9.1 List of Tables • Table 1: Market Size by Drug Types (2024–2030) • Table 2: Market Size by Indications (2024–2030) • Table 3: Market Size by Distribution Channels (2024–2030) • Table 4: Key Market Players and Their Market Share
9.2 List of Figures • Figure 1: Market Dynamics Overview • Figure 2: Growth Trends by Drug Types • Figure 3: Market Share by Indications • Figure 4: Distribution Channel Analysis
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done, and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macro-economic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of United Kingdom market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of United Kingdom Irinotecan Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of United Kingdom Irinotecan Market for the past year and forecasts for the next six years. United Kingdom Irinotecan Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different United Kingdom Irinotecan Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for United Kingdom Irinotecan Market from different application industries in different regions.
Segmentation Drug Types • Generic Irinotecan o Irinotecan Hydrochloride o Liposomal Irinotecan o Others • Branded Irinotecan o Onivyde (Liposomal Irinotecan) o Camptosar • Others o Experimental Formulations
Indications • Colorectal Cancer o Stage III Colorectal Cancer o Stage IV Colorectal Cancer o Others • Lung Cancer o Non-Small Cell Lung Cancer (NSCLC) o Small Cell Lung Cancer (SCLC) • Pancreatic Cancer o Advanced Pancreatic Cancer o Metastatic Pancreatic Cancer • Others
Distribution Channels • Hospital Pharmacies o Public Hospitals o Private Hospitals • Retail Pharmacies o Independent Pharmacies o Chain Pharmacies • Online Pharmacies
